Similar articles

• Clinical efficacy of ofloxacin in acute exacerbations of chronic respiratory disease.

  Watanabe K, Yoshida M, Ishibashi T, Yamada H, Kido M, Hirose T, Maeda F, Matsuzaki Y. Watanabe K, et al. Drugs. 1995;49 Suppl 2:448-50. doi: 10.2165/00003495-199500492-00131. Drugs. 1995. PMID: 8549396 Clinical Trial. No abstract available.
• Causative organisms in acute exacerbation of chronic airways disease and response to ofloxacin therapy.

  Sufarlan AW, Zainudin BM, Pit S, Ishak I. Sufarlan AW, et al. Drugs. 1995;49 Suppl 2:442-5. doi: 10.2165/00003495-199500492-00129. Drugs. 1995. PMID: 8549394 Clinical Trial. No abstract available.
• Clinical evaluation of levofloxacin 200 mg 3 times daily in the treatment of bacterial lower respiratory tract infections.

  Kawai T. Kawai T. Drugs. 1995;49 Suppl 2:416-7. doi: 10.2165/00003495-199500492-00119. Drugs. 1995. PMID: 8549383 Clinical Trial. No abstract available.
• [Levofloxacin in the treatment of respiratory infections].

  Iakovlev SV, Iakovlev VP. Iakovlev SV, et al. Antibiot Khimioter. 2002;47(8):32-42. Antibiot Khimioter. 2002. PMID: 12515095 Review. Russian. No abstract available.
• [The present and future of levofloxacin in the treatment of respiratory infections].

  García-Rodríguez JA, Muñoz Bellido JL, Alonso Manzanares MA, Gutiérrez Zufiaurre MN. García-Rodríguez JA, et al. Enferm Infecc Microbiol Clin. 1999;17 Suppl 1:53-8. Enferm Infecc Microbiol Clin. 1999. PMID: 10563113 Review. Spanish. No abstract available.